Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786959 | 0.89 | BRD4 (0.41) | TRPV1BRD9LMNAPOLBRXFP1 | |
| SCHEMBL28444082 | 0.88 | CHRM3 (0.52) | BRD9CHRM3LMNACHRM2CHRM1 | |
| SCHEMBL3786206 | 0.86 | CYP17A1 (0.42) | TRPV1BRD9RXFP1 | |
| SCHEMBL3786212 | 0.86 | MAP4K4 (0.42) | TRPV1BRD9RXFP1BRD4CREBBP | |
| Acetic Acid SCHEMBL1157172 | 0.85 | CHRM3 (0.50) | BRD9CHRM3LMNACHRM2CHRM1 | |
| SCHEMBL6831599 | 0.85 | ALDH1A1 (0.45) | LMNAPOLB | |
| SCHEMBL3783577 | 0.85 | CHRM3 (0.54) | TRPV1BRD9CHRM3LMNARXFP1 | |
| SCHEMBL6831601 | 0.84 | SOAT1 (0.44) | LMNAIDO1 | |
| SCHEMBL3792928 | 0.83 | BRD9 (0.46) | TRPV1BRD9CHRM3LMNARXFP1 | |
| SCHEMBL3783569 | 0.83 | BRD9 (0.46) | BRD9CHRM3RXFP1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | TRPV1 1353/4885BRD9 247/4885CHRM3 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.